Utility of routine ultrasonography follow-up after total thyroidectomy in patients with papillary thyroid carcinoma: a single-center study

Ha Kyoung Park, Dong Wook Kim, Tae Kwun Ha, Young Jin Heo, Jin Wook Baek, Yoo Jin Lee, Young Jun Cho, Dong Kun Lee, Do Hun Kim, Soo Jin Jung, Ki Jung Ahn, Hye Shin Ahn, and Hye Jin Baek

Abstract

Background: This study aimed to assess the appropriate number of sessions and interval of routine follow-up ultrasonography (US) in patients who underwent total thyroidectomy for papillary thyroid carcinoma (PTC).

Methods: Between January 2008 and December 2009, 569 patients underwent total thyroidectomy for PTC. Of the 569 patients, 44 were excluded from the study because of no US follow-up data for the neck (n = 43) or owing to indeterminate tumor recurrence/persistence (n = 1). The follow-up US for all the patients was performed by a single radiologist. Based on the cytohistopathological results, tumor recurrence/persistence was determined.

Results: In the 525 patients, the mean interval to the last follow-up US was 54.7 months, and the mean number of follow-up US sessions was 4.4. Of the 525 patients, 31 (5.9%) showed nodal (n = 30) and non-nodal (n = 1) tumor recurrence/persistence. Patient age and N stage were independently associated with tumor recurrence/persistence. Among patients showing tumor recurrence/persistence after total thyroidectomy, the time at first detection of suspicious US findings on follow-up US was ≤8 months in 2 patients, between 10 and 23 months in 21, and ≥25 months in 8. In a receiver operating characteristic curve analysis, the number of sessions and interval of the provided follow-up US were inappropriate for the detection of tumor recurrence/persistence.

Conclusions: For the detection of tumor recurrence/persistence after total thyroidectomy in PTC patients, routine US follow-up with a 1- or 2-year interval may be excessive.

Keywords: Papillary thyroid carcinoma, Total thyroidectomy, Ultrasonography, Follow-up, Recurrence, Surveillance

Background

Papillary thyroid carcinoma (PTC) is the most common histopathological type of thyroid cancer [1]. However, patients with PTC have a good prognosis because of the indolent nature of the disease [2]. To date, surgical resection is the first-line treatment method for PTC [1]. Although the type of surgery performed depends on multiple factors, such as extrathyroidal extension, nodal metastasis, and patient age, many institutions recommended the use of total thyroidectomy or lobectomy [1, 3, 4]. For avoiding incomplete resection, optimized surgery on the basis of the findings obtained on preoperative imaging, histopathological analysis, and clinico-laboratory analysis is recommended [2]. Nevertheless, tumor recurrence of PTC is common after total thyroidectomy [3, 5–7]. Most cases of tumor recurrence have been found in the regional lymph nodes [2]. For the detection of tumor recurrence in PTC patients, various diagnostic methods including laboratory analysis; whole body scan with radioiodine; and ultrasonography (US), computed tomography, or magnetic resonance imaging have been used.

After surgery, most PTC patients periodically undergo US rather than computed tomography or other imaging modalities to detect locoregional tumor recurrence in
the neck [8–10]. US is a commonly used technique for evaluating tumor recurrence because it provides accurate information regarding the lesion size, shape, internal architecture, and vascularity [9, 11]. Unlike computed tomography, US does not involve any radiation hazard. The US features suggestive of metastatic lymph nodes from PTC include nodal enlargement, loss of the fatty hilum, hyperechogenicity, cystic change, microcalcifications, and peripheral vascularity [1]. However, no specific US features have been established for metastatic lymph nodes from PTC. In addition, a diagnosis based on US findings is operator dependent.

Recently, one study demonstrated that an early routine follow-up US in short intervals after lobectomy in patients with papillary thyroid microcarcinoma might be unnecessary [12]. However, the appropriate interval of follow-up US after total thyroidectomy in PTC patients is still unclear. Physicians or institutions use different intervals of routine follow-up US. The unnecessary follow-up US can result in a substantial economic burden to patients. Therefore, this study aimed to assess the appropriate number of sessions and interval of follow-up US in patients who underwent total thyroidectomy for the treatment of PTC.

Methods

Patients

Between January 2008 and December 2009, 569 patients underwent total thyroidectomy for the treatment of PTC in our hospital. After total thyroidectomy, patients underwent routine neck US examinations in our hospital, to detect tumor recurrence or nodal metastasis. Of the 569 patients, 43 did not undergo postoperative follow-up US and 1 revealed indeterminate results regarding tumor recurrence/persistence. These patients were excluded from the study. Ultimately, 525 patients (460 women and 65 men, age range, 8–83 years; mean age, 47.6 ± 11.3 years) were included. The institutional review board approved this retrospective study, and the need for informed consent was waived.

Total thyroidectomy

Total thyroidectomy with a low-collar incision was performed by two independent surgeons with different levels of thyroid surgery experience (29 years and 2 years, respectively). In our hospital, total thyroidectomy was performed for PTC patients with suspicious perithyroidal extension or suspicious nodal metastasis on preoperative imaging including US or computed tomography. Bilateral central nodal dissection was performed in all the cases of total thyroidectomy. The location and size of the primary PTC, perithyroidal extension, nodal metastasis, and multiplicity were investigated on the basis of histopathological results. T and N stages were determined on the basis of the eighth edition of the American Joint Committee on Cancer staging system [13].

Follow-up neck ultrasonography

A single radiologist (with 6 years of thyroid and neck US experience performing > 4000 US/year) performed the follow-up US examinations by using a high-resolution ultrasound instrument (HDI 5000 or iU 22; Philips Medical Systems, Bothell, WA, USA) equipped with a 5–15-MHz linear probe. In PTC patients in our hospital, postoperative follow-up US in PTC patients is routinely performed at 1- or 2-year intervals. In follow-up US, the following features were investigated on real-time examination: the presence of a newly developed mass in the postoperative thyroid bed and perithyroidal neck area, the presence of a suspicious lymph node in the neck, and US interval changes in the previous mass or in the lymph nodes in the neck. In the literature, suspicious US features of nodal metastasis from PTC include an intranodal cystic component, diffusely increased echogenicity, microcalcification, an irregular margin, and taller-than-wide shape [14, 15].

Determination of tumor recurrence/persistence

Tumor recurrence/persistence was divided as nodal and non-nodal: nodal tumor recurrence/persistence was defined as the nodal metastasis from PTC on histopathological examinations, whereas non-nodal tumor recurrence/persistence was defined as the presence of PTC in the postoperative thyroid bed or perithyroidal neck area. During the follow-up period after total thyroidectomy, tumor recurrence/persistence was determined by US-guided fine-needle aspiration, core needle biopsy, or surgery.

Statistical analysis

The normal distribution of continuous data was tested with the Kolmogorov-Smirnov test. Normally distributed variables were compared by using an independent t-test. According to the T stage, N stage, number of follow-up US sessions, and mean intervals of follow-up US, one-way analysis of variance (ANOVA) with the post-hoc Tukey’s test was used for analyzing significant differences among each item. Data are presented as the mean ± standard deviation. Group comparisons of categorical variables were performed by using the Chi-square test and Fisher’s exact test. A receiver operating characteristic (ROC) curve was constructed to determine the intervals and number of follow-up US sessions, with the largest value of area under the ROC curve (Az). A cutoff value for each variable was determined by maximizing the sum of the sensitivity and specificity. The Az values were compared by using the method of DeLong et al. [16]. Multivariate logistic regression analysis was used to investigate the relationships between tumor recurrence/persistence and each item. Statistical significance was accepted as p values less than 0.05. All statistical analyses were performed using the IBM SPSS Statistics 19.0 software package (SPSS, Chicago, IL, USA).
**Results**

In the 525 included patients, the mean size of the primary PTC was 12.2 ± 8.5 mm (range, 1.8–55.2 mm). The location of the primary PTC was the right lobe in 264 patients, the left lobe in 242, and the isthmus in 19. The T stage was T1a in 278 patients, T1b in 167, T2 in 71, T3a in 7, T3b in 2, T4a in 0, and T4b in 0. The N stage was N0 in 253 patients, N1a in 226, and N1b in 46. Among the 525 patients, there was a solitary PTC in 292 and multiple PTCs in 233. The mean interval from total thyroidectomy to the last follow-up US was 54.7 ± 22.7 months (range, 5–91 months), and the mean number of follow-up US sessions was 4.4 ± 1.8 (range, 1–9).

Of the 525 patients, 31 (5.9%) showed tumor recurrence/persistence: nodal tumor recurrence/persistence in 30 (Fig. 1) and non-nodal in 1. The non-nodal recurrence was found in the postoperative thyroid bed after surgical excision. The final diagnostic method of tumor recurrence/persistence included US-guided fine-needle aspiration in 9 patients and surgical excision in 22. In the tumor recurrence/persistence group, the mean size of the primary PTC was 16.9 ± 9.4 mm (range, 6.4–46 mm). The location of the primary PTC was the right lobe in 20 and the left lobe in 11. The T stage was T1a in 6 patients, T1b in 16, T2 in 8, and T3a in 1. The N stage was N0 in 5 patients, N1a in 18, and N1b in 8. Of the 31 patients with tumor recurrence/persistence, there was a solitary PTC in 13 and multiple PTCs in 18. The mean interval of the last follow-up US was 50.9 ± 26.3 months (range, 10–83 months), and the mean number of follow-up US sessions was 4.3 ± 2.2 (range, 1–9). The mean interval of the follow-up US at the first detection of tumor recurrence/persistence was 19.2 ± 11.7 months (range, 7–50 months).

The data indicating the T stage, N stage, interval of the last follow-up US, and tumor recurrence/persistence are summarized in Table 1. With regard to the T stage, there was no significant difference in the interval of the last follow-up US ($p = 0.595$), whereas there was a significant difference in the tumor recurrence/persistence ($p = 0.001$). For the N stage, there was no significant difference in the interval of the last follow-up US ($p = 0.096$), whereas there was a significant difference in the tumor recurrence/persistence ($p < 0.0001$).

The relationship between multiple factors and tumor recurrence/persistence in PTC patients who underwent total thyroidectomy was analyzed by multivariate logistic regression analysis (Table 2). Patient age (odds ratio [OR], 0.96; 95% confidence interval [CI]: 0.93, 0.99) and N stage (OR, 2.49; 95% CI: 1.32, 4.71) were significantly and independently associated with tumor recurrence/persistence, whereas the other factors revealed no significant association. The patients with tumor recurrence/persistence (mean age, 40.9 ± 13.9 years) were younger than those without tumor recurrence/persistence (mean age, 48.0 ± 11.0 years). The tumor recurrence/persistence rate was higher in patients with N1b tumors compared to patients with N1a or N0 tumors. However, there was a

---

| Table 1 | Tumor Recurrence/Persistence | Total Follow-Up US Sessions | Total Follow-Up US | T Stage | N Stage | Interval (Months) | N Stage |
|---------|------------------------------|-----------------------------|-------------------|---------|---------|------------------|---------|

*Fig. 1* A 45–50-year-old patient with tumor recurrence/persistence of papillary thyroid carcinoma (PTC) in a regional lymph node. Before thyroid surgery, a longitudinal gray-scale sonogram (a) showed a primary PTC in the right lobe (9.6 mm in the largest diameter). On the 44-month follow-up ultrasonography after total thyroidectomy, transverse (b) and longitudinal (c) gray-scale sonograms showed a suspicious lymph node with intranodal microcalcifications and diffusely increased echogenicity in the right lower neck (arrows, 6.6 x 8.2 x 11.0 mm). On the transverse color-Doppler sonogram (d), a suspicious lymph node showed an increased vascularity. After US-guided fine-needle aspiration for this node, nodal metastasis of PTC was diagnosed on cytology. After consecutive nodal dissection, nodal metastasis was confirmed on histopathological analysis.
significant difference in the initial tumor size between the recurrence and non-recurrence groups according to an independent t-test \((p = 0.007)\).

The analysis results of follow-up US and tumor recurrence/persistence are listed in Table 3. There was a significant association between the number of follow-up US sessions and the interval of the last follow-up US \((p = 0.037)\) and between the number of follow-up US sessions and tumor recurrence/persistence \((p = 0.042)\). Of the 31 patients with tumor recurrence/persistence after total thyroidectomy, suspicious tumor recurrence/persistence was detected on follow-up US in ≤8 months in 2 patients, between 10 and 23 months in 21, and ≥25 months in 8. In addition, the number of patients with tumor recurrence/persistence was high at the 2nd, 5th, and 6th US follow-up sessions.

ROC curve analysis of factors such as the number of sessions and the interval of follow-up US showed no statistical significance in the detection of tumor recurrence/persistence (Table 4). The diagnostic performance related to follow-up US for evaluating tumor recurrence/persistence is shown in Fig. 2. After total thyroidectomy in PTC patients, we found that the number of sessions and the interval of the follow-up US were inappropriate for the detection of tumor recurrence/persistence.

**Discussion**

The recurrence of PTC includes locoregional nodal recurrence, locoregional non-nodal recurrence, and distant metastasis [2]. Nodal recurrence in the neck represents 90% or more of tumor recurrence in postoperative PTC patients [2]. In the present study, most of the tumor recurrence/persistence cases were the locoregional type (96.8%, 30/31) and only 1 case with locoregional non-nodal recurrence/persistence was found. Based on the literature, locoregional recurrence rates after total thyroidectomy in PTC patients range from 5 to 20% [3, 5–7]. The reason for this diversity may be related to

**Table 1** The T/N stage and tumor recurrence/persistence in 525 patients who underwent total thyroidectomy for papillary thyroid carcinoma

| T stage | Interval of the last follow-up US (month: mean ± SD, range) | Tumor recurrence/persistence (%) |
|---------|----------------------------------------------------------|----------------------------------|
| T1a \((n = 278)\) | 53.7 ± 22.9 (5-90) | 6 (2.2) |
| T1b \((n = 167)\) | 55.4 ± 23.1 (8-91) | 16 (9.6) |
| T2 \((n = 71)\) | 57.0 ± 20.2 (10-84) | 8 (11.3) |
| T3a \((n = 7)\) | 64.6 ± 23.5 (14-84) | 1 (14.3) |
| T3b \((n = 2)\) | 54 ± 2.8 (52-56) | 0 |
| T4a \((n = 0)\) | NA | NA |
| T4b \((n = 0)\) | NA | NA |
| N stage | Interval of the last follow-up US (month: mean ± SD, range) | Tumor recurrence/persistence (%) |
| N0 \((n = 253)\) | 53.1 ± 22.9 (5-90) | 2.0 (5) |
| N1a \((n = 226)\) | 55.1 ± 22.7 (6-91) | 8.0 (18) |
| N1b \((n = 46)\) | 60.9 ± 21.9 (0-89) | 17.4 (8) |

Note. US ultrasonography, SD standard deviation, NA not available

**Table 2** Multivariate logistic regression analysis of factors predicting tumor recurrence/persistence in 525 patients who underwent total thyroidectomy for papillary thyroid carcinoma

| Items | Odds ratioa | P value |
|-------|-------------|---------|
| Patient age | 0.96 (0.93, 0.98) | 0.011 |
| Sex | 1.20 (0.38, 3.84) | 0.759 |
| Size of primary PTC | 1.00 (0.92, 1.10) | 0.932 |
| Location of primary PTC | 0.56 (0.27, 1.20) | 0.136 |
| T stage | 1.62 (0.64, 4.10) | 0.305 |
| N stage | 2.41 (1.27, 4.58) | 0.007 |
| Multiplicity | 1.88 (0.85, 4.17) | 0.119 |
| Interval of the last follow-up US | 0.96 (0.92, 1.01) | 0.058 |
| Number of follow-up US session | 1.49 (0.91, 2.46) | 0.116 |

Note. aNumbers in parentheses are 95% confidence intervals

**Table 3** Follow-up ultrasonography and tumor recurrence/persistence in 525 patients who underwent total thyroidectomy for papillary thyroid carcinoma

| Number of follow-up US sessions | Interval of the last follow-up US (month: mean ± SD, range) | Tumor recurrence/persistence (%) |
|--------------------------------|----------------------------------------------------------|----------------------------------|
| 1 \((n = 58)\) | 13.9 ± 11.8 (5-58) | 3 (5.2) |
| 2 \((n = 57)\) | 26.1 ± 14.8 (10-73) | 7 (12.3) |
| 3 \((n = 29)\) | 40.5 ± 13.3 (19-70) | 1 (3.4) |
| 4 \((n = 64)\) | 55.3 ± 11.2 (30-81) | 4 (6.3) |
| 5 \((n = 169)\) | 64.1 ± 9.4 (45-90) | 6 (3.6) |
| 6 \((n = 114)\) | 71.8 ± 6.7 (55-89) | 6 (5.3) |
| 7 \((n = 28)\) | 78.0 ± 9.0 (55-91) | 2 (7.1) |
| 8 \((n = 4)\) | 82.0 ± 0.8 (81-83) | 1 (25) |
| 9 \((n = 2)\) | 82.5 ± 2.1 (81-84) | 1 (50) |

Note. US ultrasonography, SD standard deviation
the different cohort sizes, subtypes of PTC, different percentage of high risk patients, and follow-up interval [7]. In the present study, the tumor recurrence/persistence rate was low (5.9%) compared to that obtained in the previous studies [3, 5–7]. The tumor recurrence rate may increase when the follow-up interval becomes longer.

In PTC patients, tumor recurrence may be associated with the mortality rate [5]. The decrease or prevention of tumor recurrence is a major concern for most clinicians [17]. The known risk factors for tumor recurrence of PTC include the tumor size, extrathyroidal extension, T stage, and N stage [18, 19]. However, tumor recurrence may be influenced by the number of tumors, follow-up interval, and subtypes of PTC [7]. In the present study, only young age and high N stage were independently associated with tumor recurrence. The reason for discordance in the results is not clear, but it may be associated with the absence of T4 stage cases and the low prevalence of T3 stage tumors (n = 9, 1.7%).

For the detection of tumor recurrence after surgery in PTC patients, various methods including laboratory analysis, whole body scan with radioiodine, US, and computed tomography have been used [1]. Unlike serum thyroglobulin measurement or whole-body scans, US can be used to localize a tumor recurrence lesion [10]. Moreover, US can detect tumor recurrences in patients with undetectable serum thyroglobulin levels and negative whole body scan [11]. Thus, postoperative follow-up US has been used widely. Based on the results of the previous study, nodal recurrence in the neck is commonly detected within the first 3-4 years after surgery in PTC patients [20]. In the present study, the majority of nodal recurrence cases were detected on follow-up US within the first 1-2 years (the 1st and 2nd US follow-up sessions). In addition, tumor recurrence/persistence was observed to be high at the 5th and 6th US follow-up sessions, although this might be related to the high prevalence of these session groups (53.9%, 283/525). This result suggests that only 1 or 2 sessions of routine follow-up US within the first 5 years after total thyroidectomy in PTC patients is sufficient for the detection of tumor recurrence/persistence. For example, the first follow-up US can be performed 1-2 years after total thyroidectomy and the second follow-up US can be performed 4-6 years after total thyroidectomy. For confirming these results, a large-scale multi-center study is required.

This study had several limitations. First, all the patients were not included in the study. Of the 569 patients, 44 (7.7%) were excluded because of absent postoperative follow-up US data and indeterminate tumor recurrence/persistence. Second, the frequency and interval of follow-up US were variable. Furthermore, the mean interval of the last follow-up US was 54.7 months, and there were no cases with the last follow-up US > 8 years. Third, no laboratory findings, computed tomography findings, or whole-body scans with radioiodine were included, although postoperative measurements of serum thyroglobulin and thyroid-stimulating hormone levels have been routinely performed in our hospital. However, these findings might influence the detection of tumor recurrence/persistence. Fourth, individual US features, distant metastasis, and pathological subtypes of PTC were not investigated. Finally, we could not distinguish tumor recurrence from persistence.

### Table 4 Multivariate logistic regression analysis of factors predicting tumor recurrence/persistence in 525 patients who underwent total thyroidectomy for papillary thyroid carcinoma

| Items           | $A_z$ value* | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Cut off | $P$ value |
|-----------------|--------------|----------------|-----------------|---------|---------|---------|-----------|
| Number of session | 0.513 (0.469, 0.556) | 32.3           | 78.7            | 8.7     | 94.9    | 2       | 0.828     |
| Interval        | 0.514 (0.470, 0.558) | 38.7           | 77.5            | 9.8     | 95.3    | 39      | 0.814     |

*Numbers in parentheses are 95% confidence intervals

Note. $A_z$ indicates the largest area under the receiver operating characteristic curve

PPV positive predictive value, NPV negative predictive value

Fig. 2 Diagnostic performance of the number of sessions and interval of follow-up ultrasonography for detecting tumor recurrence/persistence after total thyroidectomy in patients with papillary thyroid carcinoma. The diagonal line indicates 50% of the area under the receiver operating characteristic curve and refers to a hypothetical marker that has no power for discriminating a tumor recurrence from a non-recurrence.
Conclusion
This study demonstrated that the tumor recurrence/persistence rate after total thyroidectomy in PTC patients was low, and that the majority of tumor recurrence/persistence cases were detected on follow-up US between 1 and 2 years after total thyroidectomy. Thus, routine US follow-up with a 1- or 2-year interval for the detection of tumor recurrence/persistence may be excessive, and a new algorithm for routine follow-up US should be established.

Additional file

Additional file 1: Raw data in 525 PTC patients who underwent total thyroidectomy. The data file includes size and location of primary PTC, T/N stage, multiplicity, interval and session number of follow-up US, interval of the last follow-up US, interval between total thyroidectomy and first US detection of tumor recurrence, the presence or absence of tumor recurrence, and the site of tumor recurrence. (XLS 89 kb)

Abbreviations
CI: Confidence interval; OR: Odds ratio; PTC: Papillary thyroid carcinoma; ROC: Receiver operating characteristic; US: Ultrasonography

Availability of data and materials
All data are presented within the manuscript and Additional file 1.

Authors’ contributions
DW made study concept and design, and was a major contributor in completing the study. All authors took part in the previous journal research and investigated patient data, and HK wrote the manuscript draft. HJ performed statistical analysis, and HJ, HK, and DW interpreted the patient data. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study design was approved by the institutional review boards of Inje University Busan Paik Hospital (IRB 2015-0281), and the need for informed consent was waived owing to the retrospective design of the study.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 1 August 2017 Accepted: 30 April 2018
Published online: 15 May 2018

References
1. Haugen BR, Alexander EK, Bible KC, Doherty G, Mandel SJ, Nihill J, et al. American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(13):1331–45.
2. Grant CS. Recurrence of papillary thyroid cancer after optimized surgery. Gland Surg. 2015;5:52–62.
3. Pisanu A, Recca I, Nardello O, Uccheddu A. Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors. World J Surg. 2009;33:460–8.
4. Macedo FI, Mittal VK. Total thyroidectomy versus lobectomy as initial operation for small unilateral papillary thyroid carcinoma: a meta-analysis. Surg Oncol. 2011;20:117–22.
5. Grant CS, Hay ID, Gough RJ, Bergstralh EJ, Goellner JR, McConahey WM. Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery. 1988;104:954–62.
6. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–28.
7. Lim YS, Lee JC, Lee YS, Lee BJ, Wang SG, Son SM, et al. Lateral cervical lymph node metastases from papillary thyroid carcinoma: predictive factors of nodal metastasis. Surgery. 2011;150:116–21.
8. Torlontano M, Attard M, Crocetti U, Timuno S, Bruno R, Costante G, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab. 2004;89:3602–7.
9. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, et al. Management of thyroid nodules detected at US: Society of Radiologists in ultrasound consensus conference statement. Radiology. 2005;237:794–800.
10. Perttari H, Laitinen K, Schallin-Jantti C, Valimaki MJ. Long-term outcome of 495 TNM stage I or II patients with differentiated thyroid carcinoma followed up with neck ultrasonography and thyroglobulin measurements on T4 treatment. Clin Endocrinol. 2008;69:323–31.
11. Frasoldati A, Perenti M, Gallo M, Caroggi A, Salvo D, Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer. 2003;97:90–6.
12. Kim DW. Long-term follow-up ultrasonography after lobectomy in papillary thyroid microcarcinoma patients: a single-center study. Endocr Res. 2016;41:213–7.
13. Perrier ND, Brierley JD, Tuztle RM. Differentiated and anaplastic thyroid carcinoma major changes in the American joint committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; https://doi.org/10.3322/caac.21439. [Epub ahead]
14. Kim DW, Choo HJ, Lee YJ, Jung SJ, Eom JW, Ha TK. Sonographic features of the cervical lymph node following thyroidecomy for papillary thyroid carcinoma. J Ultrasound Med. 2013;32:1173–80.
15. Lee YJ, Kim DW, Park HK, Kim DH, Jung SJ, Oh M, et al. Preoperative ultrasound diagnosis of nodal metastasis in papillary thyroid carcinoma patients according to nodal compartment. Ultrasound Med Biol. 2015;41:1294–300.
16. Delong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–45.
17. Roh JL, Park JY, Rha KS, Park CI. Is central neck dissection necessary for the treatment of lateral cervical nodal recurrence of papillary thyroid carcinoma? Head Neck. 2007;29:901–6.
18. Baek SK, Jung KY, Kang SM, Kwon SJ, Woo JS, Cho SH, et al. Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid. 2010;20:147–52.
19. Ito Y, Kudo T, Kobayashi K, Miya A, Ichihara K, Miyauchi A. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. World J Surg. 2012;36:1274–8.
20. Durante C, Montesano T, Torlontano M, Attard M, Monzani F, Timuno S, et al. Papillary thyroid cancer: time course of recurrences during post surgery surveillance. J Clin Endocrinol Metab. 2013;98:636–42.